Literature DB >> 23471536

New treatment options for lennox-gastaut syndrome.

Monica E Lemmon1, Eric H Kossoff.   

Abstract

OPINION STATEMENT: Lennox-Gastaut syndrome (LGS) is one of the most difficult epilepsy syndromes to treat, and many children are refractory to standard treatment regimens. Valproic acid, topiramate, and lamotrigine are considered first-line therapies. Newer agents, including clobazam and rufinamide, are promising additions to the current treatment options. The ketogenic diet and vagus nerve stimulation are important adjuncts, with increasing evidence to support their use. Corpus callosotomy should be considered in refractory cases. Finally, focal resective surgery should be considered in patients with lesional disease, although for most patients with LGS this is unlikely to be the case.

Entities:  

Year:  2013        PMID: 23471536     DOI: 10.1007/s11940-013-0223-z

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  38 in total

Review 1.  Callosotomy for intractable epilepsy: overall outcome.

Authors:  A Rougier; B Claverie; J M Pedespan; C Marchal; P Loiseau
Journal:  J Neurosurg Sci       Date:  1997-03       Impact factor: 2.279

2.  Efficacy of the ketogenic diet in Lennox-Gastaut syndrome: a retrospective review of one institution's experience and summary of the literature.

Authors:  Monica E Lemmon; Naomi N Terao; Yu-Tze Ng; Wayne Reisig; James E Rubenstein; Eric H Kossoff
Journal:  Dev Med Child Neurol       Date:  2012-03-22       Impact factor: 5.449

Review 3.  Therapeutic devices for epilepsy.

Authors:  Robert S Fisher
Journal:  Ann Neurol       Date:  2012-02       Impact factor: 10.422

4.  Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group.

Authors:  J Motte; E Trevathan; J F Arvidsson; M N Barrera; E L Mullens; P Manasco
Journal:  N Engl J Med       Date:  1997-12-18       Impact factor: 91.245

5.  Vagus nerve stimulation in children with refractory seizures associated with Lennox-Gastaut syndrome.

Authors:  M Frost; J Gates; S L Helmers; J W Wheless; P Levisohn; C Tardo; J A Conry
Journal:  Epilepsia       Date:  2001-09       Impact factor: 5.864

6.  Levetiracetam in the treatment of Lennox-Gastaut syndrome.

Authors:  Emily C De Los Reyes; Gregory B Sharp; Jane P Williams; Sue E Hale
Journal:  Pediatr Neurol       Date:  2004-04       Impact factor: 3.372

Review 7.  Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy.

Authors:  Wolfgang Löscher
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

8.  A modified Atkins diet is effective for the treatment of intractable pediatric epilepsy.

Authors:  Eric H Kossoff; Jane R McGrogan; Renee M Bluml; Diana J Pillas; James E Rubenstein; Eileen P Vining
Journal:  Epilepsia       Date:  2006-02       Impact factor: 5.864

Review 9.  Treatment of Lennox-Gastaut syndrome.

Authors:  Eleanor C Hancock; Helen H J Cross
Journal:  Cochrane Database Syst Rev       Date:  2009-07-08

10.  Pediatric epilepsy surgery in focal lesions and generalized electroencephalogram abnormalities.

Authors:  Ajay Gupta; Adina Chirla; Elaine Wyllie; Deepak K Lachhwani; Prakash Kotagal; William E Bingaman
Journal:  Pediatr Neurol       Date:  2007-07       Impact factor: 3.372

View more
  4 in total

Review 1.  Epileptic encephalopathies: new genes and new pathways.

Authors:  Sahar Esmaeeli Nieh; Elliott H Sherr
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

Review 2.  Experience in the use of clobazam in the treatment of Lennox-Gastaut syndrome.

Authors:  Gabriela Purcarin; Yu-Tze Ng
Journal:  Ther Adv Neurol Disord       Date:  2014-05       Impact factor: 6.570

Review 3.  Treatment-resistant Lennox-Gastaut syndrome: therapeutic trends, challenges and future directions.

Authors:  Adam P Ostendorf; Yu-Tze Ng
Journal:  Neuropsychiatr Dis Treat       Date:  2017-04-20       Impact factor: 2.570

4.  Genetic basis of pediatric epilepsy syndromes.

Authors:  Dongli Zhang; Xiaoming Liu; Xingqiang Deng
Journal:  Exp Ther Med       Date:  2017-03-27       Impact factor: 2.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.